Biotech
Commented by Juliane Zielonka on December 23rd, 2024 | 11:55 CET
Pharma stocks in focus: Setback for Novo Nordisk, spot-on performance for Vidac Pharma and Bayer
Updates from the pharmaceutical and biotech sector for investors: The Danish company Novo Nordisk is experiencing a setback in the development of its new weight loss drug, CagriSema. Vidac Pharma and Bayer, on the other hand, have positive news to report. The biotech company has received an extension of patent protection for its innovative cancer drugs from the US Patent Office, presenting a unique opportunity for investors. Bayer is also celebrating a success: the higher-dose version of the eye drug Eylea has delivered convincing results in the latest study. This means that in the future, patients will require less frequent injections into the eye. We take a closer look at the developments.
Read
Commented by Fabian Lorenz on December 23rd, 2024 | 08:05 CET
Takeover candidates 2025: Plug Power, Evotec, Desert Gold
Will Plug Power be taken over, or is there a risk of a sharp drop in the share price? The latter is possible in the coming weeks, and shareholders must be careful. A hot takeover candidate in the gold sector is Desert Gold. Analysts see significant upside potential, and the Company is convincing with an exciting mix: production is expected to start in 2025, the resource has increased to 2 million ounces, and gold producers with deep pockets are active in the neighbourhood. At Evotec, a takeover attempt – albeit an amateurish one – has already failed this year. Will financial investor Triton make a serious bid in 2025, or will Deutsche Bank prove right with a target price of EUR 4?
Read
Commented by Fabian Lorenz on December 19th, 2024 | 07:00 CET
Evotec, Rheinmetall, Vidac Pharma: Buy recommendation, cancer revolution, or price collapse?
Analysts see significant potential for multiplication with Vidac Pharma's stock. It has already been one of the standout performers in the biotech sector in the second half of the year. The Company aims to revolutionize cancer treatment and has published the next top news. Analysts also see further price potential for Rheinmetall. However, shareholders should brace themselves for a possible significant correction in the share price of Germany's largest defense contractor. By contrast, opinions on Evotec remain divided. Is the share price at risk of halving again after a year to forget? Or is now the time to buy in?
Read
Commented by Juliane Zielonka on December 13th, 2024 | 07:00 CET
Medical milestones from Novo Nordisk, BioNxt and Bayer: New hope for millions of patients
Medical research is currently making remarkable progress in the treatment of serious diseases. Three companies in this field are reporting important developments that could improve the lives of many people: the Danish pharmaceutical company Novo Nordisk is consolidating its leading position in the fight against obesity with a market share of over 30% in GLP-1 drugs and is driving global expansion. At the same time, the Canadian company BioNxt Solutions is developing a groundbreaking MS therapy: an innovative and simple administration could significantly ease the daily medication routine for MS patients. Bayer, in turn, is starting an important study for a novel cancer drug that is expected to be particularly effective against aggressive tumour types due to its unique mechanism of action. The specific benefits offered by the new therapies and how they change patients' lives are factors that investors should consider when making their next investment decisions.
Read
Commented by Stefan Feulner on December 10th, 2024 | 07:30 CET
Novo Nordisk, BioNxt Solutions, Bayer – The market continues to boom
The weight-loss drug market was one of the fastest-growing sectors in the past year and shows no signs of slowing down in 2025. Companies like Novo Nordisk have seen their valuations multiply in recent years, significantly boosting their market capitalization. At the same time, smaller life sciences companies in the second tier, such as those with breakthrough technologies, offer interesting entry opportunities.
Read
Commented by André Will-Laudien on December 10th, 2024 | 07:00 CET
Biotech Acquisitions in 2025: Several 100% Gains Expected – Evotec, Vidac Pharma, BioNTech, and Pfizer
There have already been two attempts, but the story continues! Evotec speculators were confronted with a rumor mill and a takeover bid in November. This is what happens when a stock plummets and languishes for a long time. The management wisely rejected Halozyme's undervalued offer, and thus, the bidding war for the Hamburg-based company began anew. In the biotech sector, eyes should now be on the future, as the first movements have already taken place. In our stock selection, there are three outliers with price increases of more than 30% in the last 3 months. However, the big moves will only take place in 2025. Here is an analytical look at a long-neglected sector.
Read
Commented by Armin Schulz on December 5th, 2024 | 07:15 CET
Evotec has exploded – Will BioNxt Solutions and Bayer follow suit?
The biotechnology and pharmaceutical industries are among the most advanced and forward-looking sectors of the global economy. With the development of innovative drugs, therapies, and technologies, the industry is pursuing the goal of sustainably improving the quality of life of millions of people. Intensive research, enormous investments, and a strong focus on groundbreaking innovations define this field, where science and technology work together in close cooperation. Companies such as Evotec, Bayer, and BioNxt Solutions are among the most interesting players in Germany. We take a look at the latest developments.
Read
Commented by Fabian Lorenz on December 4th, 2024 | 07:10 CET
CAUTION with Bayer! Is Evotec facing a SLUMP? 123fahrschule stock with 200% POTENTIAL?
After convincing quarterly figures, analysts have reaffirmed their "Buy" recommendations for the 123fahrschule share. The development of the operating cash flow is seen as particularly positive. Revenues and profits are expected to increase significantly in the coming years, with experts estimating the fair value of the stock to be more than 200% above the current level. Evotec remains under pressure. Following the failed acquisition, a board member is now also leaving the Company. Analysts are divided: will the share price rise to EUR 14 or fall to EUR 4? And what is Bayer doing? According to analysts, the shaken pharmaceutical and agrochemical giant is facing a challenging year ahead. Will margins fall again in 2025? Will the share price follow suit?
Read
Commented by Armin Schulz on December 2nd, 2024 | 07:20 CET
Evotec, Vidac Pharma, BioNTech – Cancer research: The gold mine in the portfolio
Investing in publicly traded companies active in oncology research offers promising returns and long-term stability. The oncology market is one of the fastest-growing sectors in healthcare and benefits from an ever-increasing demand for innovative and personalized cancer therapies. Advances such as CAR-T cell therapies and antibody-drug conjugates are revolutionizing treatment options and creating new opportunities for companies and investors. At the same time, the sector is characterized by a low dependence on economic fluctuations and a high level of dynamism in mergers and acquisitions. With long-term trends such as an aging population, this market offers solid prospects for investors. We take a look at three promising companies.
Read
Commented by Fabian Lorenz on November 28th, 2024 | 07:30 CET
PRICE SURGE or SELL-OFF: Buy BioNTech? Is Evotec on the verge of a slump? BioNxt Solutions share on the brink of a breakout?
Price opportunity with BioNxt! If the innovative biotech stock breaks out of its sideways movement since September, a quick 50% gain could be possible. In any case, things are going well operationally. The Company is developing next-generation drug delivery systems. The Evotec share is not for the faint-hearted. After the price jump following the takeover offer, a sharp drop followed. Analysts see the fair value of the biotech company well below the current price. Will takeover speculation continue? The BioNTech share has avoided slipping below EUR 100. Analysts view the data on the breast cancer candidate positively and recommend buying.
Read